160 related articles for article (PubMed ID: 36645189)
21. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
22. Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue - A pilot study.
Valtcheva N; Nguyen-Sträuli BD; Wagner U; Freiberger SN; Varga Z; Britschgi C; Dedes KJ; Rechsteiner MP
Exp Mol Pathol; 2021 Dec; 123():104705. PubMed ID: 34637782
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
[TBL] [Abstract][Full Text] [Related]
24. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.
Staff S; Nupponen NN; Borg A; Isola JJ; Tanner MM
Genes Chromosomes Cancer; 2000 Aug; 28(4):432-42. PubMed ID: 10862052
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
Martinez Chanza N; Bernard B; Barthelemy P; Accarain A; Paesmans M; Desmyter L; T'Kint de Roodenbeke D; Gil T; Sideris S; Roumeguere T; Hamid AA; Sweeney CJ
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):199-207. PubMed ID: 34108647
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
27. Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
Oliva L; Lozano R; Llácer C; Aragón I; Pajares BI; Sáez MI; Herrera-Imbroda B; Montesa A; Hernández D; Villatoro R; Otero A; Correa R; Grau G; Peinado P; Pacheco MI; García-Galisteo E; Rueda A; Machuca FJ; Alba E; Márquez-Aragonés A; Olmos D; Castro E
Eur Urol Oncol; 2021 Apr; 4(2):315-318. PubMed ID: 31307957
[TBL] [Abstract][Full Text] [Related]
28. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
29. Assessment of ovarian reserve and reproductive outcomes in
Ponce J; Fernandez-Gonzalez S; Calvo I; Climent M; Peñafiel J; Feliubadaló L; Teulé A; Lázaro C; Brunet JM; Candás-Estébanez B; Durán Retamal M
Int J Gynecol Cancer; 2020 Jan; 30(1):83-88. PubMed ID: 31780568
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
[TBL] [Abstract][Full Text] [Related]
31. BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
Kirchhoff T; Kauff ND; Mitra N; Nafa K; Huang H; Palmer C; Gulati T; Wadsworth E; Donat S; Robson ME; Ellis NA; Offit K
Clin Cancer Res; 2004 May; 10(9):2918-21. PubMed ID: 15131025
[TBL] [Abstract][Full Text] [Related]
32. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
33. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
[TBL] [Abstract][Full Text] [Related]
34. Benchmarking of Amplicon-Based Next-Generation Sequencing Panels Combined with Bioinformatics Solutions for Germline BRCA1 and BRCA2 Alteration Detection.
Vendrell JA; Vilquin P; Larrieux M; Van Goethem C; Solassol J
J Mol Diagn; 2018 Nov; 20(6):754-764. PubMed ID: 30055349
[TBL] [Abstract][Full Text] [Related]
35. Implementing NGS-based
Rivera D; Paudice M; Gismondi V; Anselmi G; Vellone VG; Varesco L;
J Clin Pathol; 2021 Sep; 74(9):596-603. PubMed ID: 32895300
[TBL] [Abstract][Full Text] [Related]
36. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
37. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
38. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract][Full Text] [Related]
39. Molecular characteristics of Asian male BRCA-related cancers.
Kwong A; Ho CYS; Shin VY; Ng ATL; Chan TL; Ma ESK
Breast Cancer Res Treat; 2023 Apr; 198(2):391-400. PubMed ID: 36637704
[TBL] [Abstract][Full Text] [Related]
40. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]